Model-Informed Drug Development (MIDD) improves drug discovery by reducing waste, limiting animal testing, and optimising trials. I presented a mechanistic PBPK model for mRNA-LNP monoclonal antibodies that accurately predicts pharmacokinetics, identifies key bottlenecks, and supports sustainable development of new mRNA-based therapies.